What's breaking now, across thousands of outlets.
Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
The news doesn’t stop when markets close. Hosts David Gura, Christina Ruffini and Lisa Mateo bring clarity, context and a bit of humor to the weekend’s biggest headlines, LIVE from New York.
The inflow follows ₹20,200 crore invested in July, marking a sharp turnaround after four consecutive months of heavy selling
The ADT on the NSE fell to a five-month low in August as investors turned cautious amid sharp price volatility and widespread profit-booking
A financial model that could cut the cost of installing solar panels for many homeowners is welcomed by Alexis Abramson The UK proposal to use “solar bonds” to make rooftop solar more affordable is a…
